Effects of Probucol versus Aspirin and versus Brachytherapy on Restenosis after Femoropopliteal Angioplasty: The PAB Randomized Multicenter Trial

Abstract

Purpose:

To evaluate the effect of probucol and/or of endovascular brachytherapy (EVBT) on restenosis after percutaneous transluminal angioplasty (PTA) of femoropopliteal arteries.

Methods:

A total of 335 patients (206 men; mean age 72±9 years) with intermittent claudication were randomized according to a 2×2 factorial design to 1 of the 4 groups: probucol, placebo, EVBT, and EVBT+probucol. Probucol (1 g/d) or placebo were given in double-blinded fashion 1 month before and for 6 months after PTA. Gamma irradiation (¹⁹²Iridium, 14 Gy, 5-mm reference depth) was randomly applied in an unblinded manner from a noncentered endoluminal catheter. All patients received aspirin (100 mg/d). Primary endpoint was restenosis (>50% diameter reduction) detected by duplex ultrasound 6 months after PTA. Secondary endpoints included clinical and hemodynamic assessment.

Results:

Restenosis in patients undergoing EVBT was 17% (23/133) versus 35% (50/142) in patients without EVBT (p<0.001); in patients treated with probucol versus placebo, the rates were 23% (31/135) and 30% (43/140, p<0.001). Three quarters (77%, 102/133) of patients were free of claudication after EVBT therapy versus 61% (87/142) without EVBT (p<0.05). Need for target vessel revascularization was 6% (8/133) with EVBT versus 14% (20/142) without EVBT (p<0.01). Late thrombotic occlusions occurred in 4% (6/133), exclusively in patients treated with EVBT after stent implantation.

Conclusions:

Endovascular brachytherapy significantly reduces restenosis, improves symptoms, and reduces reinterventions after PTA of femoropopliteal arteries. Probucol reduces restenosis but has no additive effect when combined with brachytherapy.

Keywords

angioplasty restenosis brachytherapy probucol peripheral vascular disease femoropopliteal segment multicenter trial

Get full access to this article

View all access options for this article.

References

Gallino

Mahler

Probst

. Percutaneous transluminal angioplasty of the arteries of the lower limbs: A 5-year follow-up. Circulation. 1984; 70: 619–623.

Mintz

Weissman

Fitzgerald

. Intravascular ultrasound assessment of the mechanisms and results of brachytherapy. Circulation. 2001; 104: 1320–1325.

Côté

Tardif

Lespérance

. Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation. 1999; 99: 30–35.

Waksman

White

Chan

. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Washington Radiation for In-Stent Restenosis Trial (WRIST) Investigators. Circulation. 2000; 101: 2165–2171.

Teirstein

Massullo

Jani

. Three-year clinical and angiographic follow-up after intracoronary radiation: Results of a randomized clinical trial. Circulation. 2000; 101: 360–365.

King

Williams

Chougule

. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: Results of the beta energy restenosis trial (BERT). Circulation. 1998; 97: 2025–2030.

Verin

Popowski

de Bruyne

. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med. 2001; 344: 243–249.

Leon

Teirstein

Moses

. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001; 344: 250–256.

Minar

Pokrajac

Maca

. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Results of a prospective randomized study. Circulation. 2000; 102: 2694–2699.

10.

Zehnder

von Briel

Baumgartner

. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. J Endovasc Ther. 2003; 10: 304–311.

11.

Tardif

Côté

Lespérance

. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997; 337: 365–372.

12.

Rutherford

Becker

. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology. 1991; 181: 277–281.

13.

Jäger

Phillips

Martin

. Noninvasive mapping of lower limb arterial lesions. Ultrasound Med Biol. 1985; 11: 515–521.

14.

Ranke

Creutzig

Alexander

. Duplex scanning of the peripheral arteries: Correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992; 18: 433–440.

15.

Lan

Wittes

. The B-value: A tool for monitoring data. Biometrics. 1988; 44: 579–585.

16.

Bonvini

Baumgartner

. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. J Am Coll Cardiol. 2003; 41: 409–412.

17.

Corti

Wyttenbach

Alerci

. Effect of percutaneous transluminal angioplasty on severely stenotic femoral lesions: In vivo demonstration by noninvasive magnetic resonance imaging. Circulation. 2002; 106: 1570–1571.

18.

Waksman

Bhargava

Mintz

. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol. 2000; 36: 65–68.

19.

Minar

Wolfram

Pokrajac

. Endovascular brachytherapy and late thrombotic occlusion [Letter]. Circulation. 2000; 102: e175–e176.

20.

Waksman

Ajani

Pinnow

. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis. Washington Radiation for In-stent Restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation. 2002; 106: 776–778.

21.

Lau

Leichtweis

Hume

. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation. 2003; 107: 2031–2036.

22.

Klein

. QT-interval prolongation produced by probucol. Arch Intern Med. 1981; 141: 1102–1103.

23.

Morice

Serruys

Sousa

. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. RAVEL Study Group. N Engl J Med. 2002; 346: 1773–1780.

24.

Duda

Pusich

Richter

. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation. 2002; 106: 1505–1509.

25.

Faxon

. Systemic drug therapy for restenosis: “déjà vu all over again.” Circulation. 2002; 106: 2296–2298.

26.

Wyttenbach

Gallino

Alerci

. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation. 2004; 110: 1156–1161.